Calcitonin injection (Salmocalcin) - sanofi-aventis
Alternative Names: Salcatonin injection - sanofi-aventis; Salmocalcin; Salmocalcin BaseLatest Information Update: 24 Sep 2021
At a glance
- Originator Sanofi Winthrop
- Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
- Mechanism of Action Calcitonin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypercalcaemia; Osteitis deformans; Postmenopausal osteoporosis
Most Recent Events
- 20 Jul 2012 The European Medicines Agency recommended that due to an increased risk of cancer associated with long-term use, calcitonin medicines should only be used for the shortest possible time using the minimum effective dose .
- 27 Aug 2004 Sanofi-Synthélabo has merged with Aventis to form Sanofi-Aventis.
- 27 Aug 1999 Sanofi and Synthélabo have merged to form Sanofi-Synthélabo